Back to search results

Observational Study for Parkinson's Disease and GBA Gene Mutations

This study by the New York Stem Cell Foundation (NYSCF) Research Institute aims to accelerate Parkinson's disease research and drug development. Researchers are collecting biological samples (like skin, blood, or saliva) from people with Parkinson's disease, Gaucher disease, or healthy individuals. These samples will be used to create stem cells and other cell types, perform genetic testing, and store for future research. The goal is to build a diverse bank of these samples and information to help identify future treatments or cures for Parkinson's disease. You can join if you are 18 or older and have Parkinson's disease, Gaucher disease, or are a healthy control. The study's main goal is to establish this sample bank.

Study design
This is an observational study with a planned enrollment of 60 participants. It is not a clinical trial, meaning no experimental treatments are being tested.
What's involved
Participation involves completing health questionnaires, providing a skin and/or blood sample, and a saliva sample. There may also be future follow-up for additional information or other research studies.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05536388

Drug Discovery for Parkinson's With Mutations in the GBA Gene

UNKNOWN
Not specifiedAges 18+Observational
New York Stem Cell Foundation Research Institute
~60 participants
Updated 2025-03-03 on ClinicalTrials.gov
What's tested:Biological Sample Collection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Establishment of a diverse bank of biological samples, stem cell lines, derivatives, and associated information.
Measured over Baseline

Conditions

Parkinson Disease
Gaucher Disease
Healthy
GBA Gene Mutation

Explore related trials

Gaucher DiseaseParkinson Disease

NCT05536388

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • The New York Stem Cell Foundation Research Institute

    New York, New Yorkstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Laura Andres-Martin · PRINCIPAL_INVESTIGATOR · New York Stem Cell Foundation Research Institute

Who to contact

Clinical Research Office
[email protected]
212-927-1801
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older.
Diagnosis of Parkinson's disease, Gaucher disease, or healthy control.
Must provide written informed consent unless physical limitations preclude signing.

Exclusion

For skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection.
For blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection.
For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocols will be excluded. Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.

What this trial measures

  • Establishment of a diverse bank of biological samples, stem cell lines, derivatives, and associated information.Baseline

    Establish a robust disease signature using a cohort of PD and carefully matched control samples to screen a library of approximately 3,000 compounds to determine whether any compounds improve or reverse disease phenotypes.